Holen Sie sich die Stockscreener-App
13.33
1.72%
0.2228
Schlusskurs vom Vortag:
$13.11
Offen:
$13.08
24-Stunden-Volumen:
669.65K
Relative Volume:
0.35
Marktkapitalisierung:
$4.25B
Einnahmen:
$3.05B
Nettoeinkommen (Verlust:
$181.32M
KGV:
35.68
EPS:
0.3737
Netto-Cashflow:
$225.64M
1W Leistung:
+4.71%
1M Leistung:
+6.85%
6M Leistung:
+14.07%
1J Leistung:
+76.86%
1-Tages-Spanne:
$13.08
$13.41
1-Wochen-Bereich:
$12.38
$13.41
52-Wochen-Spanne:
$7.02
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, TEVA, HLN, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
13.33 | 4.18B | 3.05B | 181.32M | 225.64M | 0.3737 |
TAK
Takeda Pharmaceutical Co Adr
|
16.54 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.57 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.65 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.215 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
574.07 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | UBS | Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
How The Amneal Pharmaceuticals (AMRX) Story Is Shifting Around The New US$17 Price Target - Yahoo Finance
Earnings call transcript: Amneal Pharma Q1 2026 Surpasses EPS Forecast By Investing.com - Investing.com Canada
Earnings call transcript: Amneal Pharma Q1 2026 Surpasses EPS Forecast - Investing.com
Amneal (AMRX) Q3 2025 Earnings Call Transcript - AOL.com
Amneal Pharmaceuticals Q1 2026 earnings preview - MSN
How CREXONT’s Positive Phase 4 Data and Reaffirmed Outlook Could Shape Amneal Pharmaceuticals (AMRX) Investors - Sahm
AMRX growth drivers: Generics, biosimilars, and Crexont - MSN
3 Biotech Stocks to Watch for Respectable Growth Beyond AI - AOL.com
Artemis Investment Management LLP Buys Shares of 124,899 Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Wall Street analysts see a 34.77% upside in Amneal (AMRX): Can the stock really move this high? - MSN
Amneal (AMRX) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings Scheduled For May 1, 2026 - Benzinga
UBS Initiates Coverage of Amneal Pharmaceuticals (AMRX) With a Bullish Outlook - Yahoo Finance
Here's how AMRX is tapping GLP-1 demand through manufacturing - MSN
Amneal to buy Kashiv in $750M deal; raises FY26 EPS outlook - MSN
Amneal Q1 2026 slides: $750M Kashiv deal creates biosimilar leader - Investing.com India
Earnings call transcript: Amneal Pharma Q1 2026 beats EPS forecast By Investing.com - Investing.com India
Is It Too Late To Reassess Amneal Pharmaceuticals (AMRX) After Its 65% One-Year Surge? - simplywall.st
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat
Amneal (AMRX) Q1 Earnings Report Preview: What To Look For - StockStory
Amneal (AMRX) Q1 earnings report preview: What to look for - MSN
Amneal Pharma to acquire Kashiv BioSciences to create fully integrated global biosimilar leader - MSN
AMRX: 3 growth drivers behind Amneal's 2026 outlook - MSN
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals (AMRX) is a top-ranked momentum stock: Should you buy? - MSN
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High? - Yahoo Finance
Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now? - Yahoo Finance
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
AMRX Should I Buy - Intellectia AI
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 - Quantisnow
Amneal 2026-2027 Upside From Biosimilars Scale - Zacks Investment Research
AMRX Valuation: What 1.69x Sales Means for Investors - Yahoo Finance
AMRX Growth Drivers: Generics, Biosimilars, and Crexont - Yahoo Finance
BlackRock (NYSE: AMRX) holds 24.1M shares, 7.6% stake reported - Stock Titan
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock - Yahoo Finance
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
2.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):